β-catenin degrader
/ Coltac Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
Targeting Beta-catenin in colorectal cancer: Novel molecular glue drug candidates by Coltac's BOND+ platform
(AACR 2026)
- "Coltac's BOND+ platform enabled rapid discovery and validation supporting therapeutic drugs for β-catenin. We demonstrated potent antitumor activity highlighting Coltac's molecular glue as a new drug candidate in β-catenin-driven cancers."
Colorectal Cancer • Desmoid Tumors • Endometrial Cancer • Hepatocellular Cancer • Oncology • Ovarian Cancer • Sarcoma • Solid Tumor • CTNNB1
1 to 1
Of
1
Go to page
1